Technical Analysis for CRVS - Corvus Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 1.65% | |
| Oversold Stochastic | Weakness | 1.65% | |
| 50 DMA Resistance | Bearish | -1.07% | |
| Stochastic Buy Signal | Bullish | -1.07% | |
| Gapped Up | Strength | -1.07% | |
| Oversold Stochastic | Weakness | -1.07% | |
| Crossed Above 200 DMA | Bullish | 3.35% | |
| NR7 | Range Contraction | 3.35% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 8 hours ago |
| Rose Above Previous Day's High | about 8 hours ago |
| Rose Above 10 DMA | about 8 hours ago |
| Up 3% | about 8 hours ago |
| Up 2% | about 8 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/06/2024
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that plan to initiate a Phase 1/1b clinical trial for adenosine, an immune checkpoint. The company also develops a product candidate, an anti-CD73 monoclonal antibody that inhibits the production of adenosine. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Immunology Immune System Cancer Immunotherapy Monoclonal Antibody Cancer Cell Immune Checkpoint Adenosine Oncology Therapies Cd73
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Immunology Immune System Cancer Immunotherapy Monoclonal Antibody Cancer Cell Immune Checkpoint Adenosine Oncology Therapies Cd73
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.16 |
| 52 Week Low | 1.05 |
| Average Volume | 239,514 |
| 200-Day Moving Average | 1.78 |
| 50-Day Moving Average | 1.93 |
| 20-Day Moving Average | 1.98 |
| 10-Day Moving Average | 1.84 |
| Average True Range | 0.15 |
| RSI (14) | 44.13 |
| ADX | 20.77 |
| +DI | 12.99 |
| -DI | 19.19 |
| Chandelier Exit (Long, 3 ATRs) | 1.82 |
| Chandelier Exit (Short, 3 ATRs) | 2.24 |
| Upper Bollinger Bands | 2.28 |
| Lower Bollinger Band | 1.68 |
| Percent B (%b) | 0.28 |
| BandWidth | 30.08 |
| MACD Line | -0.06 |
| MACD Signal Line | -0.03 |
| MACD Histogram | -0.0232 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.00 | ||||
| Resistance 3 (R3) | 2.00 | 1.94 | 1.97 | ||
| Resistance 2 (R2) | 1.94 | 1.91 | 1.94 | 1.97 | |
| Resistance 1 (R1) | 1.90 | 1.88 | 1.92 | 1.90 | 1.96 |
| Pivot Point | 1.84 | 1.84 | 1.86 | 1.85 | 1.84 |
| Support 1 (S1) | 1.80 | 1.81 | 1.82 | 1.80 | 1.74 |
| Support 2 (S2) | 1.74 | 1.78 | 1.75 | 1.73 | |
| Support 3 (S3) | 1.70 | 1.74 | 1.73 | ||
| Support 4 (S4) | 1.70 |
